Johnson & Johnson

Momenta Pharmaceuticals is a biotechnology company that specializes in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. The company also utilizes its ability to sequence the molecular structure of sugars to create technology-enabled generic versions of complex sugar-based products. Its advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox, an often-prescribed low molecular weight heparin. The company s technology provides a better understanding of the roles that sugars play in cellular function, disease and drug action. Momenta Pharmaceuticals is headquartered in Cambridge, Mass.

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website